Eternygen GmbH announced that it has received €8 million in its series A round of equity funding led by Epidarex Capital on January 9, 2017. The round included participation from a consortium of prominent German investors, including new investor Evotec AG (XTRA:EVT), VC Fonds Technologie Berlin; a fund managed by IBB Beteiligungsgesellschaft mbH, and two family offices.